Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MRNA vs BIIB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BIIB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

BIIB Overall Winner 6-Pillar Tally: MRNA 2 – 4 BIIB Matrix Metrics: MRNA 3 – 7 BIIB

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 46.8/100 (HOLD) at $215.96 (23.0x Forward P/E, -80.8% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin).

  • Growth vs. Quality Trade-Off: BIIB earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. MRNA 46.8/100 HOLD) and 0.27β · 36% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs BIIB
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$215.96
-3.32% 1D
Market Cap $93.6B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.35β · 101% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 41.0 Fund 50.0 Flow 67.0 Mom 41.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.4 · SMA20: $230.06 · SMA50: $203.13
BIIB NASDAQ Head-to-Head Winner
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
TTM Revenue $10.3B
Forward P/E 15.6x
Beta / 30D Vol 0.27β · 36% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $250.29 · SMA50: $234.03

6-Pillar Scorecard Institutional Category Breakdown (MRNA 2 – 4 BIIB)

Columns: Metric · MRNA · BIIB
1. Valuation Multiples BIIB
Forward P/E 23.0x 15.6x
Trailing P/E 23.0x 109.9x
PEG Ratio N/M 3.45x
EV / Revenue 38.3x 4.2x
2. Growth & Scale MRNA
Revenue Growth (YoY) +29.2% +10.6%
Earnings Growth (YoY) -85.1% -84.8%
TTM Revenue (USD) $2.52B $10.3B
Market Cap $93.6B $37.0B
3. Profitability & Quality BIIB
Gross Margin -42.0% 75.8%
Operating Margin -80.8% 23.5%
Net Profit Margin -110.5% 3.4%
Return on Equity (ROE) -34.5% 1.9%
4. Balance Sheet & Cash Flow BIIB
Cash Generation (TTM) -$2.04B $1.64B
Cash Flow Margin -81.0% 16.0%
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $6.50B Net Debt (0.41x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BIIB
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 70.5% (30th %ile) 18.4% (6th %ile)
Put/Call OI Skew 1.12x (Balanced) 0.77x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) 52.3% of Rev ($5.39B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (3) vs BIIB (7)
Institutional Metric MRNA BIIB Criterion Row Edge
Market Capitalization
Scale
$93.6B $37.0B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x 109.9x Lower Multiple MRNA
Forward P/E Ratio
Valuation
23.0x 15.6x Lower Multiple BIIB
Revenue Growth (YoY)
Growth
+29.2% +10.6% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-80.8% 23.5% Higher Margin BIIB
Net Profit Margin
Profitability
-110.5% 3.4% Higher Margin BIIB
Return on Equity (ROE)
Capital Efficiency
-34.5% 1.9% Higher ROE BIIB
52-Week Range Position
Momentum
75% ($22–$281) 92% ($160–$261) Stronger Trend BIIB
Beta / 30D Volatility
Risk Regime
2.35β · 101% Vol 0.27β · 36% Vol Lower Realized Risk BIIB
Unified Institutional Score
Composite Signal
46.8 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite BIIB
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $10.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 75.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 38.3x EV/Rev 3.45x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) $1.64B ($6.50B Net Debt (0.41x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIIB +9.57 pp
MRNA: -0.94% · BIIB: +8.63%
3M Horizon MRNA +224.1 pp
MRNA: +243.0% · BIIB: +18.9%
6M Horizon MRNA +317.19 pp
MRNA: +348.88% · BIIB: +31.69%
1Y Horizon MRNA +711.79 pp
MRNA: +765.2% · BIIB: +53.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRNA Revenue BIIB Revenue MRNA Op. Margin BIIB Op. Margin Margin Leader
FY2018 $140M $13.4B -306.0% 43.8% BIIB
FY2019 $60M $14.4B -906.8% 49.0% BIIB
FY2020 $800M $13.4B -95.0% 33.8% BIIB
FY2021 $18.5B $11.0B 72.0% 25.9% MRNA
FY2022 $19.3B $10.2B 48.9% 29.9% MRNA
FY2023 $6.85B $9.84B -61.9% 11.8% BIIB
FY2024 $3.24B $9.68B -121.9% 16.9% BIIB
FY2025 $1.94B $9.89B -158.1% 13.1% BIIB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
18d in phase · OBV NEUTRAL
Current IV 70.5%
IV Percentile 30th %ile
Put/Call OI Skew 1.12x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BIIB CONSOLIDATION
17d in phase · OBV ACCUMULATION
Current IV 18.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $93.6B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
BIIB Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($5.39B)
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs BIIB Key Questions & Quantitative Answers

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 46.8/100 (HOLD) at $215.96 (23.0x Forward P/E, -80.8% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin). Growth vs. Quality Trade-Off: BIIB earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. MRNA 46.8/100 HOLD) and 0.27β · 36% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with BIIB at +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while BIIB shifted -26.5%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($5.39B) (0 disclosures) for BIIB.

BIIB screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 38.3x EV/Revenue (-81.0% FCF margin), whereas BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus BIIB (1.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 70.5% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 1.12x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.35β · 101% Vol realized risk). By comparison, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.